Literature DB >> 26031219

Comparative pharmacokinetics of catalpol and acteoside in normal and chronic kidney disease rats after oral administration of Rehmannia glutinosa extract.

Min Zhao1, Dawei Qian1, Pei Liu1, Er-xin Shang1, Shu Jiang1, Jianming Guo1, Shu-lan Su1, Jin-ao Duan1, Leyue Du1, Jinhua Tao1.   

Abstract

In this study, a sensitive and robust ultra-performance liquid chromatography-mass spectrometry method with multiple-reaction monitoring mode was developed, validated, and applied to determine pharmacokinetics of catalpol and acteoside in normal and doxorubicin-induced chronic kidney disease rats after oral administration of Rehmannia glutinosa extract. The lower limits of quantification for catalpol and acteoside in rat plasma were 2.62 and 0.61 ng/mL, with a signal-to-noise ratio of ≥10. Precision and accuracy studies showed that catalpol and acteoside plasma concentrations were within the 10% range in all studies. The extraction recoveries of catalpol and acteoside were both >68.24% and the matrix effects ranged from 96.59 to 101.62%. The method was successfully applied to the pharmacokinetic study of catalpol and acteoside after oral administration of RG extract to normal and model rats, respectively. This study might further support the traditional use of RG to treat kidney diseases clinically.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Rehmannia glutinosa extract; UPLC-MS; acteoside; catalpol; chronic kidney disease; pharmacokinetic study

Mesh:

Substances:

Year:  2015        PMID: 26031219     DOI: 10.1002/bmc.3505

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  7 in total

1.  Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin-Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity.

Authors:  Wei Wu; Rui Cheng; Hamza Boucetta; Lei Xu; Jing-Ru Pan; Min Song; Yu-Ting Lu; Tai-Jun Hang
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

Review 2.  The pharmacokinetic property and pharmacological activity of acteoside: A review.

Authors:  Yaosheng Xiao; Qun Ren; Longhuo Wu
Journal:  Biomed Pharmacother       Date:  2022-06-17       Impact factor: 7.419

3.  Catalpol alleviates adriamycin-induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro.

Authors:  Jiangnan Zhang; Ran Bi; Qiang Meng; Changyuan Wang; Xiaokui Huo; Zhihao Liu; Chong Wang; Pengyuan Sun; Huijun Sun; Xiaodong Ma; Jingjing Wu; Kexin Liu
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

4.  Catalpol reduces the production of inflammatory mediators via PPAR-γ activation in human intestinal Caco-2 cells.

Authors:  Kyoung Sik Park
Journal:  J Nat Med       Date:  2016-03-23       Impact factor: 2.343

5.  Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.

Authors:  Lu Gan; Xiaozhao Li; Mengyuan Zhu; Chen Chen; Huimin Luo; Qiaoling Zhou
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

Review 6.  Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety.

Authors:  Ying Bai; Ruyuan Zhu; Yimiao Tian; Rui Li; Beibei Chen; Hao Zhang; Bingke Xia; Dandan Zhao; Fangfang Mo; Dongwei Zhang; Sihua Gao
Journal:  Molecules       Date:  2019-09-11       Impact factor: 4.411

Review 7.  Research Progress and Trends of Phenylethanoid Glycoside Delivery Systems.

Authors:  Jin Huang; Dandan Zhao; Chaojing Cui; Jianxiong Hao; Zhentao Zhang; Limin Guo
Journal:  Foods       Date:  2022-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.